KSQ Therapeutics Welcomes Kristen Hege, M.D. as Board Member
KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology firm dedicated to creating innovative treatments for solid tumors, has recently announced a pivotal addition to their Board of Directors: Kristen Hege, M.D. With a remarkable background in oncology and cell therapy spanning over two decades, Dr. Hege is poised to contribute significantly to KSQ's growth and strategic direction.
Expertise in Cancer Treatment
Dr. Hege's experience includes substantial leadership roles in oncology. She has successfully advanced numerous clinical programs through various stages, culminating in FDA approvals. This depth of knowledge positions her perfectly to guide KSQ as they push forward with their engineered tumor-infiltrating lymphocyte (eTIL) programs.
Impactful Leadership at KSQ
Chief Executive Officer Qasim Rizvi expressed enthusiasm about Dr. Hege joining the board, noting, "Kristen brings deep industry and clinical experience to our board. Her insights and counsel will be incredibly valuable as we continue to move our lead eTIL programs through clinical studies." Dr. Hege's strategic vision aligns with KSQ's mission of enhancing cancer treatment through groundbreaking therapies.
Innovative eTIL Platform
Dr. Hege emphasized the potential of KSQ's eTIL platform in improving existing TIL therapies. By addressing the immunosuppressive tumor microenvironment, these therapies can effectively target tumor malignancies. The ability of eTILs to navigate the immune system's defenses marks a significant evolution in cancer treatment paradigms.
Dr. Hege’s Experience and Contributions
Before her current role, Dr. Hege served as Senior Vice President at Bristol Myers Squibb (BMS), where she oversaw the clinical development pipeline of novel therapies across hematology and oncology. Her leadership was instrumental in the approval of Abecma, a BCMA CAR-T cell therapy for multiple myeloma. This experience contributes to her unique perspective as KSQ navigates its clinical landscape.
Academic Background and Current Roles
Dr. Hege boasts an impressive academic background, having spent nearly thirty years at the University of California, San Francisco (UCSF) as a clinical faculty member. She currently serves on several boards, including those of Mersana Therapeutics and Adaptimmune, where she leverages her expertise to guide future innovations in cancer therapy.
About KSQ Therapeutics
KSQ Therapeutics is committed to addressing cancer through a range of drug modalities. Their proprietary CRISPRomics discovery engine enhances target discovery in cancer therapies. This cutting-edge technology underscores the company's goal to revolutionize treatment across diverse types of tumors.
Frequently Asked Questions
Who is Kristen Hege, M.D.?
Kristen Hege is a seasoned expert in oncology and cell therapy, recently appointed to the Board of Directors of KSQ Therapeutics.
What is KSQ Therapeutics known for?
KSQ Therapeutics is known for developing novel cancer treatments and its proprietary CRISPRomics discovery engine.
What role did Dr. Hege have at BMS?
Dr. Hege was the Senior Vice President for Early Clinical Development, overseeing advancements in cancer therapy pipelines.
How does eTIL therapy work?
eTIL therapy involves engineering tumor-infiltrating lymphocytes to enhance their ability to target and destroy solid tumors.
Why is Dr. Hege's appointment significant for KSQ?
Her extensive experience and leadership in oncology are expected to bolster KSQ's clinical strategy and innovation in cancer therapies.
